Interní Med. 2010; 12(11): 561-564

Treatment of hypertension in an internist‘s office

prof.MUDr.Miroslav Souček, CSc.1, prof.MUDr.Jiří Widimský, DrSc.sr.2, MUDr.Jiří Žižka3, MUDr.Ivan Řiháček, Ph.D.1, MUDr.Petr Fráňa1, MUDr.Martin Plachý1
1 II. interní klinika LF MU a FN u sv. Anny v Brně
2 Klinika kardiologie IKEM Praha
3 I. interní klinika, Fakultní Thomayerova nemocnice a IPVZ Praha

The aim of this paper was to ascertain what is the treatment and control of hypertension like in GP offices and in internal and cardio logy

offices. These are two papers that cannot be compared due to the different cohort composition. However, they bring data resulting

from routine clinical practice.

Keywords: risk factors, target organ damage, diagnosis and treatment of hypertension, target levels

Published: December 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Souček M, Widimský sr J, Žižka J, Řiháček I, Fráňa P, Plachý M. Treatment of hypertension in an internist‘s office. Interní Med. 2010;12(11):561-564.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Kalita Z, Souček M, Sachová M. Výskyt rizikových faktorů cévní mozkové příhody v populaci České republiky. Průzkum STOP CMP. Prakt Lék 2003; 83: 643-646.
    2. Widimský J, Sachová M, Souček M, Lánská V. Vysoká prevalence a špatná kontrola hypertenze v ordinacích praktických lékařů. Vnitřní Lék. 2005; 51: 1087-1095.
    3. Sharma A, Wittobee AH, Kirch W, et al. High prevalence and poor control of hypertension in primary care: Gross-sectional study. J Hypertens 2004; 22: 479-486. Go to original source... Go to PubMed...
    4. Widimský J, Souček M, Sachová M, Lánská V. Hypertenze a diabetes mellitus v ordinacích praktických lékařů. Výskyt hypertenze a její kontrola. Cor et Vasa 2005; 47(4): 127-132.
    5. Souček M, Widimský J, Lánská V. Control of Hypertension in Patients with Hypertension, Diabetes, and Impaired Fasting Glucose by Czech Primary Care Physicians. Kidney Blood Press Res 2006; 29: 366-372. Go to original source... Go to PubMed...
    6. Žižka J, Souček M. Evaluation of cardiovascular high risk population in Specialists Ambulance: ESA. Vnitř Lék 2010; 56(5): 376-381.
    7. Jozífová M, Cífková R, Škodová Z, et al. Porovnání léčby hypertenze a rizikového profilu hypertoniků v obecné populaci a na specializovaném pracovišti. Cor et Vasa 2003; 45: 533-541.
    8. Wald DS, Law M, Morris JK, et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11 000 participants from 42 trials. Am J Med 2009; 122: 290-300. Go to original source... Go to PubMed...
    9. Jamerson K, Weber MA, Bakris GL, et al. ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359: 2417-2428. Go to original source... Go to PubMed...
    10. Dahlöf B, Sever PS, Poulter NR, et al. ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regiment of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005; 366: 895-906. Go to original source... Go to PubMed...
    11. ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomized controlled trial. Lancet 2007; 370: 829-840. Go to original source... Go to PubMed...
    12. ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-1559. Go to original source... Go to PubMed...
    13. Zanchetti A, Grossi G, Mancia G. When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal. J Hypertens 2009; 27: 923-934. Go to original source... Go to PubMed...
    14. Sleight P, Redon J, Verdecchia P, et al. On behalf of the ONTARGET investigators. Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. J Hypertens 2009; 27: 1360-1369. Go to original source... Go to PubMed...
    15. Mancia G, Laurent S, Agabiti-Rosei L, et al. Reappraisal of European guidelines on hypertension management: a European Society of hypertension Task Force dokument. Journal of Hypertension 2009; 27(11): 2121-2158. Go to original source... Go to PubMed...
    16. Widimský J. Komentář k přehodnocení evropských doporučení léčby arteriální hypertenze. Cor et Vasa 2010; 52: 75-78. Go to original source...
    17. Jozífová M, Cífková R, Škodová Z, a kol. Léčba a kontrola hypertenze v České republice v období 1997/1998 - 2006/2009. Interní Med. 2010; 12(4): 212-217.
    18. Widimský J jr, Cífková R, Špinar J, et al. Doporučení diagnostických a léčebných postupů u arteriální hypertenze - verze 2007. Doporučení České společnosti pro hypertenzi. Vnitř Lék 2008; 1: 101-118.

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.